LAEKNA-B

2105
6.6252.00% ( -0.135 )
Delay Closed: Nov 16, 16:08:11

Overview

LAEKNA-B (2105)

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic dise...

Open
6.500
High
6.780
Low
6.300
Prev. Close
6.760
Volume
1.09M
Turnover
7.24M
Avg Price
6.628
Bid/Ask Ratio
33.33%
Amplitude
7.10%
52wk High
19.360
Volume Ratio
0.93
Turnover Ratio
0.24%
52wk Low
5.295
HK Mkt Cap
2.99B
Market CapHKD
2.99B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.260
EPSDynamic
-0.0130
EPSStatic
--
BVPS
3.05
P/B
2.17
HK Shares
452.06M
Dividend YieldTTM
--
DividendTTM
--
Shares
452.06M
Min lot size
500
Currency
HKD

LAEKNA-B Analyst Rating

View more

Forecast & Rating

Aug 26, 2026
Price forecast
HK$23.36252.60%
Forecast & RatingStrong buy
3analysts
  • Strong buy66.67%
  • Buy33.33%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Laekna Inc. rose sharply today, closing at HKD 7.800, up 6.70% from the previous close, with a turnover of HKD 15.1 million and a turnover rate of 0.44%. The stock gained momentum in the afternoon session, hitting an intraday high of HKD 7.850 after a low of HKD 7.330, forming a low-open high-go pattern. Q3 2025 revenue surged 24,927.84% YoY to HKD 55.9 million, but net loss narrowed only 11.11% to HKD 54.5 million, with EPS at -HKD 0.1353. Despite the losses, the stock price remains well below its 52-week high, and the market's focus on its pipeline progress drove the rally. However, the net profit margin remains deeply negative at -97.53%, underscoring the company's pre-revenue stage.

  2. Jul, 2

    来凯医药今日放量上涨 9.7%,收报 7.37 港元,主因公司披露最高达 5600 万港元的场内股份回购计划,由董事长吕向阳及主要股东等内部人士支持,直接提振市场信心。盘中走势呈探底回升:上午盘一度从 7.13 港元开盘后冲高至 7.45 港元,但随即回落至 6.9 港元日内低点,下午盘逐步回升至收盘高位,全天成交额 4604 万港元,为近期较活跃水平。股价当前仍较 52 周高点 20.9 港元下跌 65%,YTD 跌幅 45.8%,且处于 20 日均线 8.23 港元和 60 日均线 12.64 港元之下,价格位置偏弱。财报方面,Q4 2025 营业收入达 5683 万港元,同比大增超 264 倍,净亏损收窄至 5542 万港元,EPS 亏损 0.14 港元同比改善 15.9%,基本面边际改善。此外,公司近期授予 Vasque Bio LAE118 的大中华区外全球权益,产品管线持续推进。不过,公司仍处于研发阶段尚无商业化产品,且近期高管秘书有人员变动。

News